Citations

Showing 10 of 108104 citations.

International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node-Positive Melanoma at Major Referral Centers
Broman, Kristy K., Hughes, Tasha M., Bredbeck, Brooke C., Sun, James, Kirichenko, Dennis, Carr, Michael J., Sharma, Avinash, Bartlett, Edmund K., Nijhuis, Amanda A.G., Thompson, John F., Hieken, Tina J., Kottschade, Lisa, Downs, Jennifer, Gyorki, David E., Stahlie, Emma, Akkooi, Alexander van, Ollila, David W., O’shea, Kristin, Song, Yun, Karakousis, Giorgos, Moncrieff, Marc, Nobes, Jenny, Vetto, John, Han, Dale, Hotz, Meghan, Farma, Jeffrey M., Deneve, Jeremiah L., Fleming, Martin D., Perez, Matthew, Baecher, Kirsten, Lowe, Michael, Bagge, Roger Olofsson, Mattsson, Jan, Lee, Ann Y., Berman, Russell S., Chai, Harvey, Kroon, Hidde M., Teras, Juri, Teras, Roland M., Farrow, Norma E., Beasley, Georgia M., Hui, Jane Yuet Ching, Been, Lukas, Kruijff, Schelto, Sinco, Brandy, Sarnaik, Amod A., Sondak, Vernon K., Zager, Jonathan S., Dossett, Lesly A., Hui, Jane Yuet Ching , Dossett, Lesly A. , Akkooi, Alexander C. J. van , Bagge, Roger Olofsson , Kroon, Hidde M. , Hui, Jane Yuet Ching , Olofsson Bagge, Roger , Broman, Kristy K., Hughes, Tasha M., Bredbeck, Brooke C. , Sun, James, Kirichenko, Dennis, Carr, Michael J., Sharma, Avinash, Bartlett, Edmund K., Nijhuis, Amanda A.G., Thompson, John F., Hieken, Tina J., Kottschade, Lisa, Downs, Jennifer, Gyorki, David E., Stahlie, Emma, Ollila, David W., O’shea, Kristin, Song, Yun, Karakousis, Giorgos, Moncrieff, Marc, Nobes, Jenny, Vetto, John, Han, Dale, Hotz, Meghan, Farma, Jeffrey M., Deneve, Jeremiah L., Fleming, Martin D., Perez, Matthew, Baecher, Kirsten, Lowe, Michael, Mattsson, Jan, Lee, Ann Y., Berman, Russell S., Chai, Harvey, Teras, Juri, Teras, Roland M., Farrow, Norma E., Beasley, Georgia M., Hui, Jane Yuet Ching, Been, Lukas, Kruijff, Schelto, Sinco, Brandy, Sarnaik, Amod A., Sondak, Vernon K., Zager, Jonathan S.

Mayo Clinic

Annals of Surgery | January 29, 2022 | Volume: 277 | Issue: 5 | Pages: e1106-e1115

10.1097/sla.0000000000005370 | PMID 35129464 Get It

Objective: The aim of this study was to determine overall trends and center-level variation in utilization of completion lymph node dissection (CLND) and adjuvant systemic therapy for sentinel lymph node (SLN)-positive melanoma. Summary Background Data: Based on recent clinical trials, management options for SLN-positive melanoma now include effective adjuvant systemic therapy and nodal observation instead of CLND. It is unknown how these findings have shaped practice or how these contemporaneous developments have influenced their respective utilization. Methods: We performed an international cohort study at 21 melanoma referral centers in Australia, Europe, and the United States that treated adults with SLN-positive melanoma and negative distant staging from July 2017 to June 2019. We used generalized linear and multinomial logistic regression models with random intercepts for each center to assess center-level variation in CLND and adjuvant systemic treatment, adjusting for patient and disease-specific characteristics. Results: Among 1109 patients, performance of CLND decreased from 28% to 8% and adjuvant systemic therapy use increased from 29 to 60%. For both CLND and adjuvant systemic treatment, the most influential factors were nodal tumor size, stage, and location of treating center. There was notable variation among treating centers in management of stage IIIA patients and use of CLND with adjuvant systemic therapy versus nodal observation alone for similar risk patients. Conclusions: There has been an overall decline in CLND and simultaneous adoption of adjuvant systemic therapy for patients with SLN-positive melanoma though wide variation in practice remains. Accounting for differences in patient mix, location of care contributed significantly to the observed variation.
What Really Matters Now in Prenatal Genetics
Michie, Marsha , Allyse, Megan , Allyse, Megan A

Mayo Clinic

The American Journal of Bioethics | January 28, 2022 | Volume: 22 | Issue: 2 | Pages: 31-33

10.1080/15265161.2021.2013990 | PMID 35089842 Get It

Meeting Report: Aging Research and Drug Discovery
Meron, Esther, Thaysen, Maria, Antebi, Adam , Barzilai, Nir , Birkisdóttir, María B. , Bruening, Jens, Brunet, Anne , Cai, Shi‐Qing , Chen, Brian H. , Ermolaeva, Maria , Ewald, Collin Y. , Ferrucci, Luigi , Fortney, Kristen , Freund, Adam , Georgievskaya, Anastasia , Gladyshev, Vadim N. , Golato, Tyler, Hoejimakers, Jan, Houtkooper, Riekelt H. , Jaksch, Frank, Janssens, Georges E. , Jensen, Martin Borch , Kirkland, James L. , Kjær, Michael , Lee, Kai-Fu, Lemaı̂tre, Jean-Marc , Liaskos, David, Longo, Valter D. , Lu, Yuxuan , MacArthur, Michael R. , Maier, Andrea B. , Manakanatas, Christina, Mitchell, Sarah J. , Moskalev, Alexey , Niedernhofer, Laura J. , Ozerov, Ivan V. , Peyer, James , Radenković, Dina , Rattan, Suresh I. S. , Riedel, Christian G. , Schumacher, Björn , Smith, Ryan , Suh, Yousin , Trapp, Alexandre , Trendelenburg, Anne‐Ulrike, Valenzano, Dario Riccardo , Verburgh, Kris, Zhavoronkov, Alex , Niedernhofer, Laura J , Ferrucci, Luigi , Gladyshev, Vadim N , Thaysen, Maria , Angeli, Suzanne , Baur, Joseph A. , Bekker‐Jensen, Simon , Bischof, Evelyne Y. , Bruening, Jens, Buchwalter, Abigail L. , Cabreiro, Filipe , Florian, Maria Carolina , Glass, David J. , Golato, Tyler, Gorbunova, Vera , Jäger, Sibylle , Kaeberlein, Matt R. , Karsenty, Gérard , Keizer, Peter L.J. de , Kennedy, Brian Keith , Kroemer, Guido , Liaskos, David, Partridge, Linda , Passegue, Emmanuelle A. , Petr, Michael Angelo , Rando, Thomas A. , Rudolph, K. Lenhard , Ai, Ruixue , Serrano, Manuel , Sinclair, David , Suh, Yousin , Taub, Pam R. , Verdin, Eric , Vijg, Jan , Westendorp, Rudi G. J. , Zonari, Alessandra Arcoverde Cavalcanti , Bakula, Daniela , Scheibye‐Knudsen, Morten

Mayo Clinic

Aging | January 28, 2022 | Volume: 14 | Issue: 2 | Pages: 530-543

10.18632/aging.203859 Get It

Soluble SorCS1 binds the insulin receptor to enhance insulin sensitivity
Kjølby, Mads , Wellner, Niels, Sørensen, Karen Marie Juul, Gjessing, Anette, Vittrup, Dorthe Maria , Rotman, Maarten , Thotakura, Gangadaar, Hermey, Guido , Madsen, Peder, Prasad, Rashmi B. , Parlevliet, Edwin T., Madsen, Andreas Nygaard , Breining, Peter , Pedersen, Karen, Januliene, Dovile , Manavalan, Arulmani , Vægter, Christian Bjerggaard , Thirup, Søren , Asplund, Olof , Rensen, Patrick C.N. , Holst, Birgitte , Andersen, Olav M. , Moller, Arne, Hansen, Torben , Nykjær, Anders

Mayo Clinic

No container title available | January 28, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1299440/v1 Get It

Abstract Type 2 diabetes has reached endemic proportions and is a substantial burden for the affected patients and the society. Along with lifestyle factors, a number of genetic loci predisposing to type 2 diabetes have been identified, including SORCS1 that encodes the transmembrane receptor SorCS1. The ectodomain of SorCS1 (sol-SorCS1) is shed from plasma membranes but the biological function of this fragment is unknown. Here we show that sol-SorCS1 acts as a high-affinity binding partner for the insulin receptor to stabilize the receptor and increase insulin affinity, protein kinase B activation, and glucose uptake in myocytes. Sol-SorCS1 is liberated from adipocytes, and in diabetic patients the plasma concentration positively correlates with body mass index, but inversely with plasma glucose. In mouse models of insulin resistance, exogenous sol-SorCS1 restored insulin sensitivity. We conclude that sol-SorCS1 increases peripheral insulin sensitivity and propose sol-SorCS1 as a novel insulin sensitizing adipokine and potential antidiabetic agent.
Reconstruction of ear defects using ear lobule skin reserve
Ahn, Ji Won , Mullen, Barbara , Ali, Nora S., Vidal, Nahid Y. , Mullen, Barbara L

Mayo Clinic

International Journal of Dermatology | January 28, 2022 | Volume: 62 | Issue: 3 | Pages: No page available

10.1111/ijd.16103 | PMID 35090050 Get It

Skin in the game: an analysis of political financial contributions from U.S. dermatologists
Zheng, David X. , Mulligan, Kathleen , Cullison, Christopher R. , Haglin, Jack M. , Bordeaux, Jeremy S. , LaChance, Avery , Scott, Jeffrey F. , Mulligan, Kathleen M , Xiang, Laura , Wells, Michael W.

Mayo Clinic

International Journal of Dermatology | January 28, 2022 | Volume: 62 | Issue: 3 | Pages: No page available

10.1111/ijd.16094 | PMID 35090039 Get It

Invited Commentary: Therapeutic Endoscopy—New Technologies and Newer Frontiers
Pisipati, Sailaja , Pannala, Rahul

Mayo Clinic

RadioGraphics | January 28, 2022 | Volume: 42 | Issue: 2 | Pages: E68-E69

10.1148/rg.210208 | PMID 35089820 Get It

Duodenal Mucosal Expression of COVID-19-Related Genes in Health, Diabetic Gastroenteropathy, and Functional Dyspepsia
Deb, Brototo , O’Brien, Daniel R. , Chunawala, Zainali , Bharucha, Adil E. , Chunawala, Zainali S

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | January 28, 2022 | Volume: 107 | Issue: 6 | Pages: e2600-e2609

10.1210/clinem/dgac038 | PMID 35090021 Get It

AbstractContextSARS-CoV-2 infects the gastrointestinal tract and may be associated with symptoms that resemble diabetic gastroparesis. Why patients with diabetes who contract COVID-19 are more likely to have severe disease is unknown.ObjectiveWe aimed to compare the duodenal mucosal expression of SARS-CoV-2 and inflammation-related genes in diabetes gastroenteropathy (DGE), functional dyspepsia (FD), and healthy controls.MethodsGastrointestinal transit, and duodenal mucosal mRNA expression of selected genes were compared in 21 controls, 39 DGE patients, and 37 FD patients from a tertiary referral center. Pathway analyses were performed.ResultsPatients had normal, delayed (5 FD [13%] and 13 DGE patients [33%]; P = 0.03 vs controls), or rapid (5 FD [12%] and 5 DGE [12%]) gastric emptying (GE). Compared with control participants, 100 SARS-CoV-2-related genes were increased in DGE (FDR < 0.05) vs 13 genes in FD; 71 of these 100 genes were differentially expressed in DGE vs FD but only 3 between DGE patients with normal vs delayed GE. Upregulated genes in DGE include the SARS-CoV2 viral entry genes CTSL (|Fold change [FC]|=1.16; FDR < 0.05) and CTSB (|FC|=1.24; FDR < 0.05) and selected genes involved in viral replication (eg, EIF2 pathways) and inflammation (CCR2, CXCL2, and LCN2, but not other inflammation-related pathways eg, IL-2 and IL-6 signaling).ConclusionSeveral SARS-CoV-2-related genes were differentially expressed between DGE vs healthy controls and vs FD but not between DGE patients with normal vs delayed GE, suggesting that the differential expression is related to diabetes per se. The upregulation of CTSL and CTSB and replication genes may predispose to SARS-CoV2 infection of the gastrointestinal tract in diabetes.
Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma
Sakemura, Reona , Siegler, Elizabeth L. , Cox, Michelle J. , Larson, Daniel P. , Hansen, Michael J. , Roman, Claudia Manriquez , Schick, Kendall J. , Can, İsmail , Tapper, Erin E. , Horvei, Paulina , Fonkoua, Lionel Aurelien Kankeu , Ruff, Michael W. , Nevala, Wendy K. , Walters, Denise K., Lin, Yi , Jelinek, Diane F., Bergsagel, P. Leif , Bergsagel, P. Leif , Siegler, Elizabeth L , Cox, Michelle J , Larson, Daniel P , Manriquez Roman, Claudia , Can, Ismail , Bezerra, Evandro D , Fonkoua, Lionel Aurelien A Kankeu , Parikh, Sameer A , Kay, Neil E , Lin, Yi , Sakemura, R Leo , Hefazi, Mehrdad , Adada, Mohamad M , Bezerra, Evandro D. , Parikh, Sameer A. , Kay, Neil E. , Kenderian, Saad S.

Mayo Clinic

Blood | January 28, 2022 | Volume: 139 | Issue: 26 | Pages: 3708-3721

10.1182/blood.2021012811 | PMID 35090171 Get It

Abstract Pivotal clinical trials of B-cell maturation antigen-targeted chimeric antigen receptor T (CART)-cell therapy in patients with relapsed/refractory multiple myeloma (MM) resulted in remarkable initial responses, which led to a recent US Food and Drug Administration approval. Despite the success of this therapy, durable remissions continue to be low, and the predominant mechanism of resistance is loss of CART cells and inhibition by the tumor microenvironment (TME). MM is characterized by an immunosuppressive TME with an abundance of cancer-associated fibroblasts (CAFs). Using MM models, we studied the impact of CAFs on CART-cell efficacy and developed strategies to overcome CART-cell inhibition. We showed that CAFs inhibit CART-cell antitumor activity and promote MM progression. CAFs express molecules such as fibroblast activation protein and signaling lymphocyte activation molecule family-7, which are attractive immunotherapy targets. To overcome CAF-induced CART-cell inhibition, CART cells were generated targeting both MM cells and CAFs. This dual-targeting CART-cell strategy significantly improved the effector functions of CART cells. We show for the first time that dual targeting of both malignant plasma cells and the CAFs within the TME is a novel strategy to overcome resistance to CART-cell therapy in MM.
Reply: Using Artificial Intelligence to Measure Facial Expression following Facial Reanimation Surgery
Boonipat, Thanapoom, Hebel, Nathan, Robertson, Carrie, Bakri, Karim, Bradley, Elizabeth, Amer, Hatem, Mardini, Samir, Robertson, Carrie E. , Robertson, Carrie E , Boonipat, Thanapoom, Hebel, Nathan, Robertson, Carrie, Bakri, Karim, Bradley, Elizabeth, Amer, Hatem, Mardini, Samir

Mayo Clinic

Plastic & Reconstructive Surgery | January 28, 2022 | Volume: 149 | Issue: 3 | Pages: 594e-595e

10.1097/prs.0000000000008867 | PMID 35089289 Get It